{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029841","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.135224+00:00","generated_at":"2026-06-11T05:19:16.452952+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GT Biopharma gets Nasdaq extension to Feb 20, 2024 for bid price compliance","bullets":["Company has until Feb 20, 2024 to close at $1.00 for 10 consecutive days to regain compliance.","May consider a reverse stock split to meet the Minimum Bid Price Requirement.","No immediate effect on listing; common stock continues trading on Nasdaq Capital Market under GTBP.","No assurance that compliance will be regained; company will monitor bid price and consider options."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029841","json":"https://secwatch.observer/filing/0001493152-23-029841.json","markdown":"https://secwatch.observer/filing/0001493152-23-029841.md","text":"https://secwatch.observer/filing/0001493152-23-029841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029841/0001493152-23-029841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029841/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:19:16.452952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06d8f1e0c3eb966c79d2010e5ac0e494c6b88d5f","claim":"GT Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 22, 2023, GT Biopharma, Inc. (the “Company”) received notice from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) advising that the Staff determined the Company is eligible for an additional 180 calendar day period, or until February 20, 2024, to regain compliance with its minimum bid price requirement rule under Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) pursuant to the Nasdaq Listing Rule 5810(c)(3)(A). The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continu","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029841/0001493152-23-029841-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}